WEST PALM BEACH, FL / ACCESSWIRE / February 27, 2017 / Board-certified endocrinologist, Reza Yavari, M.D., has teamed with MedScience Research Group of West Palm Beach to empower primary care physicians to better address two of the planet’s greatest health care challenges: obesity and diabetes. On March 7, 2017 Dr. Yavari will present live at the United Nations, New York City at the Massachusetts Institute of Technology (MIT) sponsored Solve competition, along with other challenge finalists from around the world, addressing topics of worldwide significance in three categories: Refugee Education; Carbon Contributions; and Chronic Diseases.

“We are losing the global battle against obesity and diabetes,” says Yale based Dr. Yavari, founder and CEO of Beyond Care LLC, a leading lifestyle management company in Connecticut. “With international initiatives such as MIT’s Solve, we are hopeful we can reverse this critical trend.”

By 2025, it is estimated that the number of U.S. adults with diabetes will exceed 50 million. The annual cost of diabetes in the U.S. alone will soon surpass the total yearly healthcare expenditure of $3 trillion. The digital self-coaching program for obesity and diabetes proposed by Dr. Yavari and MedScience provides users a digital lifestyle change program, which is offered in a financial incentive-based model.

Solve is an initiative of MIT’s Center for Collective Intelligence and aimed at developing and implementing real and lasting solutions to the world’s greatest challenges – from education and health to energy and inequality. Solve is a community
that brings together technologists and researchers, social entrepreneurs and business leaders, policy makers, change agents, and activists from across the globe to unearth and implement solutions to specific actionable challenges.

Dr. Yavari’s proposal, “A
Digital Platform For Automated Self-Coaching For Obesity & Diabetes,” is a collaborative project with Troy Grogan, President and CEO of MedScience Research Group of West Palm Beach, Florida. “With MedScience’s efforts, we hope to roll out our digital lifestyle change program quickly in physicians’ offices and other sites to reach many people at risk of diabetic and obesity complications.”

Finalists will be judged on the novelty, feasibility, impact, and quality of their proposals. The best solutions presented at the U.N. will be selected as “Solvers” and will receive support from the Solve community and be invited to and featured prominently at Solve at MIT in May 2017.

“Our scalable, evidence-based, obesity and diabetes screening and digital coaching solution will be an invaluable service for primary care physicians and their patients to efficiently monitor obese and diabetic individuals,” says Grogan. “This noninvasive, cost effective application will provide patients and their physicians access to resources employed by highly-trained practitioners at a fraction of the cost of current intensive behavioral therapy programs for weight loss and diabetes management.” The smartphone application will offer scientifically validated, noninvasive screening, predicative weight loss targets, and digital coaching, including nutrition intervention, exercise, and behavior modification counseling.

During the voting phase, anyone (age 18+) can register free on the Solve CoLab website. To select the Yavari entry, click on https://solvecolab.mit.edu/challenges/2016/cure-chronic-diseases/c/solution/1329012 and choose, “Vote for solution.” Voting concludes on February 28, 2017.

About Reza Yavari, M.D.

Reza Yavari M.D. is a Board certified endocrinologist trained at the Yale School of Medicine. As a Founder and CEO of Beyond Care® since 2000, he has been a leader in the field of lifestyle management aimed at metabolic disorders such as diabetes and obesity.

Dr. Yavari is a regular guest on national and local radio and television stations and lectures frequently to a variety of audiences. His efforts and his book titled It Must
Be My Metabolism (McGraw-Hill) have been featured in the New York Times, the Yoga Journal, Shape Magazine, NPR, CNN News Live, More magazine, among other national press and media. His upcoming book titled Situational Coaching together with an accompanied software app called Health Lifecards will soon be available for health seekers who wish to self-coach to lose weight and reduce diabetes risk by means of therapeutic lifestyle change.

About MedScience Research Group

MedScience Research Group, Inc. (MedScience) develops proprietary diagnostic equipment and products directed for use by the primary care physician. The key criteria of such equipment and products is to provide the primary care physician with a broader avenue in which to practice evidence-based medicine where before it may have been necessary to refer the patient to a specialist. MedScience focuses on diagnostic and treatment protocols that lower medical costs to patients and insurance providers while enhancing the revenue for the primary care physician community.

Visit www.MedScienceinc.com.

Media Contact:

Elizabeth Magdaleno
+1 (800) 393-8817
liz.magdaleno@medscienceinc.com

SOURCE: MedScience Research Group, Inc.

ReleaseID: 456001

NEW YORK, NY / ACCESSWIRE / February 27, 2017 /
The Dow Jones Industrial Average continued its streak of 11 consecutive record closes with a late-day rally Friday. The Dow fell by as much as 76 points, before settling to close at 20,821.76, up 0.05 percent, or 11.44 points. The S&P 500 Index gained 0.15 percent to close at 2,367.34, while the NASDAQ Composite Index gained 0.17 percent to close at 5,845.31. High yielding dividend stocks were amongst the top benefactors Friday as falling yields on government bonds sent investors flocking to stocks with high paying dividends. The S&P 500 is currently trading at price to forward earnings ratio of close to 17.8 as compared 25-year historic average of nearly 15, according to Reuters.

Register today for a
free membership and gain access to daily research reports at: RDInvesting.com

On Friday, the yield on the 10-year Treasury note dropped to 2.31 percent. In comparison, the S&P 500 Utilities sector spiked 4.3 percent for the week ended February 24th, its largest weekly gain since the week ended July 1st, 2016. The Utilities sector currently has a dividend yield of approximately 3.5 percent, according to FactSet.

“There was concern that the market was getting tired and that we were losing momentum, but there are still significant inflows, because now even the pessimists want a piece of the action. It’s momentum driven, not fundamentally driven,” said Lawrence Glazer, Managing Partner at Mayflower Advisors.

Let’s Take a
Closer Look at Today’s Trending Tickers

8×8’s shares spiked 9.86 percent to close at $16.15 a share on Friday. The stock traded between $14.50 and $16.80 on volume of 1.82 million shares traded. Reuters has recently reported that 8×8 is currently exploring a potential sale of the company, citing people familiar with the matter. Shares of 8×8 have gained approximately 12.9 percent year-to-date.

The company reported a GAAP net loss was ($1.3 million), or ($0.01) per diluted share, for the third quarter of fiscal 2017. Total revenues were $63.7 million for the third quarter of fiscal 2017, an increase of 20 percent year-over-year. Service revenues spiked 23 percent year-over-year to $60.1 million in the fiscal third quarter 2017. The company has maintained its annual guidance of revenue for fiscal 2017 in the range of $251.0 million to $254.0 million and raised non-GAAP net income guidance to a range of $18.0 to $20.0 million. To date, the company holds 128 patents in its name.

Access Today’s 8×8 Research Report Click
Here

Restoration Hardware’s shares surged 24.41 percent to close at $31.34 a share on Friday. The stock traded between $28.60 and $33.00 on volume 14.83 million shares traded. The company expects to report adjusted net revenues of $590 million for the fourth quarter of 2016, which is in the upper range of its previous guidance range of $562 million to $592 million and above analysts’ expectations of $584.7 million. Adjusted earnings per share are expected to be $0.68 for the fourth quarter, which is also above analysts’ estimates of $0.65 per share. Shares of RH have gained approximately 2.08 percent year-to-date.

“As we exit fiscal 2016, we are now through the most uncertain stage of our transformation. As previously communicated, we have made several strategic investments and changes to our business model in fiscal 2016 that temporarily depressed financial results in the short term, and that we believe will strengthen our brand and position the business for accelerated growth in 2017 and beyond,” commented Gary Friedman, Chairman and CEO.

Access Today’s RH Research Report Click
Here

Today’s Features Includes:

8×8, Inc. (NASDAQ: EGHT)

Restoration Hardware (NYSE: RH)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 456024

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / The Dow Jones Industrial Average continued its streak of 11 consecutive record closes with a late-day rally Friday. The Dow fell by as much as 76 points, before settling to close at 20,821.76, up 0.05 percent, or 11.44 points. The S&P 500 Index gained 0.15 percent to close at 2,367.34, while the NASDAQ Composite Index gained 0.17 percent to close at 5,845.31. High yielding dividend stocks were amongst the top benefactors Friday as falling yields on government bonds sent investors flocking to stocks with high paying dividends. The S&P 500 is currently trading at price to forward earnings ratio of close to 17.8 as compared 25-year historic average of nearly 15, according to Reuters.

Register today for a
free membership and gain access to daily research reports at: RDInvesting.com

On Friday, the yield on the 10-year Treasury note dropped to 2.31 percent. In comparison, the S&P 500 Utilities sector spiked 4.3 percent for the week ended February 24th, its largest weekly gain since the week ended July 1st, 2016. The Utilities sector currently has a dividend yield of approximately 3.5 percent, according to FactSet.

Let’s Take a
Closer Look at Today’s Trending Tickers

Cempra’s shares soared 28.57 percent to close at $4.05 a share on Friday. The stock traded between $4.00 and $4.75 on volume of 21.61 million shares traded. The company has reported that its fusidic acid achieved its primary endpoint in a recent phase 3 study of oral fusidic acid in 716 patients with acute bacterial skin and skin structure infections (ABSSSI). Shares of Cempra have gained approximately 44.64 percent year-to-date.

“Considering complicated skin infections are one of the most rapidly growing reasons for hospitalizations and emergency department visits each year, the results with fusidic acid in this study are promising, especially for an outpatient population where there is a need for new oral drugs that are effective against MRSA,” said William O’Riordan, M.D., Chief Medical Officer of eStudySite, leaders in evaluating new therapeutic approaches for complicated skin infections.

Access Today’s Cempra Research Report Click
Here

Universal Display’s shares surged 20.09 percent to close at $81.00 a share on Friday. The stock traded between $73.40 and $82.50 on volume 4.78 million shares traded. The company reported a net income of $25.8 million, or $0.55 per diluted share, for the fourth quarter of 2016, compared to $18.1 million, or $0.39 per diluted share, for the fourth quarter of 2015. Revenues were $74.6 million for the fourth quarter of 2016, an increase of 20 percent when compared to a year ago. Analysts’ expectations had called for earnings of $0.42 a share, on revenues of $68.6 million, according to analysts surveyed by Thomson Reuters. The company projects revenue for the full year of 2017 to be in range of $230 million to $250 million, as compared total reported revenue of $198.9 for the year 2016. Shares of Universal Display have gained approximately 43.9 percent year-to-date.

Access Today’s Universal Display Research
Report Click Here

Today’s Features Includes:

Cempra Inc. (NASDAQ: CEMP)

Universal Display Corporation (NASDAQ: OLED)

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 456022

This document corrects and replaces the press release that was issued by Goldsource Mines Inc. today, February 27, 2017 at 9:00 AM EST.

VANCOUVER, BC / ACCESSWIRE / February 27, 2017 / Goldsource Mines Inc. (TSX-V: GXS) (FSE: G5M) (OTC PINK: GXSFF) (“Goldsource” or the “Company”) announces the grant of stock options to directors, officers, employees, and consultants exercisable for 1,750,000 common shares of the Company at a price of $0.17 per share for a five year term expiring February 21, 2021. Of the stock options granted, 50,000 will be subject to a 12 month vesting schedule pursuant to which 25% shall vest on May 21, 2017 and a further 25% shall vest every 3 months thereafter until fully vested.

ABOUT GOLDSOURCE MINES INC.

Goldsource Mines Inc. (www.goldsourcemines.com) is a Canadian resource company that is currently in the Proof of Concept Phase at its 100%-owned Eagle Mountain Gold Project, located in Guyana. Goldsource is led by an experienced management team, proven in making exploration discoveries and in project construction.

Ioannis (Yannis) Tsitos
President
Goldsource Mines Inc.

For Further Information:

Goldsource Mines Inc.
Contact: Ioannis (Yannis) Tsitos, President
Fred Cooper, Investor Relations
Telephone:+1 (604) 694-1760
Fax:+1 (604) 694-1761
Toll Free:1-866-691-1760 (Canada & USA)
Email:info@goldsourcemines.com
Website:www.goldsourcemines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Goldsource Mines Inc.

ReleaseID: 456045

Sunbelt Business Brokers provides buyers and sellers with professional and confidential valuations, business listings and marketing services

INDEPENDENCE, OH / ACCESSWIRE / February 27, 2017 / Sunbelt Business Brokers, the world’s largest business brokerage franchise, is pleased to announce the opening of a new office in Kansas City, MO. Experienced Sunbelt owner Randi Edwards brings years of professional business experience to buyers and sellers in the Kansas City region.

To learn more about Sunbelt Business Brokers Kansas City – Downtown, please visit: http://www.sunbeltnetwork.com/kansas-city-downtown-mo/.

Randi Edwards stated, “Sunbelt’s new office in Kansas City specializes in handling all aspects of buying a small to mid-size business. Our experienced team of brokers is here to provide small to middle market business owners with a high level of personal service when making a purchasing or selling decision.”

Kansas City is Missouri’s largest city and is also one of the Midwest’s largest economic centers. The city is home to a Federal Reserve Bank, a number of notable companies, in addition to being a major center for federal government agencies. Once known as an agricultural and manufacturing hub, the city has expanded its economic base into banking, finance, real estate and service industry businesses. Kansas City has attracted a growing immigrant population that focuses on small business ownership. A third-quarter 2016 national business growth survey report released by the Wendover Corporation, cited Kansas City as topping the nation with its business growth index score of 23.8 percent. This booming business climate makes Kansas City a perfect location for a new Sunbelt Business Brokers office.

“We are delighted that Randi Edwards is opening a new Sunbelt office in Kansas City. Randi has been in the business brokerage industry for over 35 years and was most recently operating Sunbelt of Seattle, the number one business brokerage office in Seattle. With her move to Kansas City, Randi will continue to help clients successfully achieve their dreams through the ownership of a small business,” added Brian Knoderer, Sunbelt’s President.

Sunbelt Business Brokers Kansas City – Downtown can be contacted at the following:

107 W. 9th St., 2nd floor

Kansas City, MO 64105

For further information, please call 816-423-2583 or contact via email: randi.edwards@sunbeltnetwork.com

Please see the website: http://www.sunbeltnetwork.com/kansas-city-downtown-mo/

About Sunbelt:

Sunbelt business brokers sell more privately held businesses than any other brokerage franchise in the world. The expansive experience and knowledge of the Sunbelt network encompasses primarily the Main Street and Middle Market segments, with select offices also specializing in Mergers and Acquisitions. Headquartered in Cleveland, Ohio, each office is individually owned and operated by highly qualified franchise owners. To learn more, visit: www.sunbeltnetwork.com.

Contact:

Ashley Gooding

agooding@merrymtg.com
216-674-0645 x642

SOURCE: Sunbelt Business Brokers

ReleaseID: 456034

NEW YORK, NY / ACCESSWIRE / February 27, 2017 /
The Biotech Industry has posted some impressive gains since Election Day and the rally has continued for the larger part of this year. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have just posted four consecutive weekly gains as of February 17th, the first time since August 2016 (iShares) and June 2016 (SPDR). While President Trump has also commented on high drug prices, the landscape appears to be easing for the industry in 2017 as Trump has also promised to speed up the FDA’s approval process and has promised a “phenomenal” tax plan for American businesses, although the market is still awaiting detailed announcements.

Register today for a
free membership and gain access to daily research reports at: RDInvesting.com

Additionally, the industry has seen a number of mergers and acquisition deals already completed this year. In January, Takeda Pharmaceutical announced a deal to acquire Ariad for $24.00 per share in cash, or approximately $5.2 billion, a premium of roughly 75 percent. The amount of M&A deals is expected to pick up rapidly in 2017 as major drug makers look to boost up revenues.

“2017 is likely to push biopharma deal making to new heights,” wrote Ernst & Young’s Andrew Forman, in a research note titled M&A Outlook and Firepower Report 2017.

“Large drug companies have been making money doing things that are artificial and unsustainable. Like price increases, inversions and financial engineering,” says Brad Loncar, a cancer-company expert at Loncar Investments. “Because those things are coming to an end and the environment for the pharma industry is becoming much more challenging, companies are having a real problem posting revenue growth,” says Loncar. “The only way they can get revenue growth is to buy it.”

Let’s Take a
Closer Look at Today’s Trending Tickers

IntelliPharmaCeutics’ shares spiked 18.60 percent to close at $2.55 a share on Friday. The stock traded between $2.50 and $2.82 on volume of 5.92 million shares traded. The company has announced that it has received final approval from the U.S. Food and Drug Administration for the Company’s abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths. The newly approved product is a generic equivalent to Glucophage XR 500 mg and 750 mg branded product sold in the United States by Bristol-Myers Squibb.

“FDA approval of our application for a generic version of Glucophage XR provides further indication that the FDA is making progress to clear its backlog of ANDA drug candidates under review, and further validation of our core drug development and regulatory capability. We are encouraged that some of the Company’s other 8 ANDA candidates may be accorded further attention soon. We are actively evaluating options to realize commercial returns from this new approval.”

Access Today’s IntelliPharmaCeutics
Research Report Click Here

Orexigen Therapeutics’ shares surged 11.56 percent to close at $4.44 a share on Friday. The stock traded between $3.80 and $4.46 on volume 538,865 million shares traded. Orexigen’s first medicine, Contrave, was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. Shares of Orexigen Therapeutics have gained approximately 155 percent year-to-date.

On January 25th, the company, in partnership with Laboratorios Farmacéuticos Rovi, S.A., announced the launch of Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).

Access Today’s Orexigen Therapeutics
Research Report Click Here

Today’s Features Includes:

IntelliPharmaCeutics Intl Inc. (NASDAQ: IPCI)

Orexigen Therapeutics, Inc. (NASDAQ: OREX)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 456025

NEW YORK, NY / ACCESSWIRE / February 27, 2017 /
The Dow Jones Industrial Average continued its streak of 11 consecutive record closes with a late-day rally Friday. The Dow fell by as much as 76 points, before settling to close at 20,821.76, up 0.05 percent, or 11.44 points. The S&P 500 Index gained 0.15 percent to close at 2,367.34, while the NASDAQ Composite Index gained 0.17 percent to close at 5,845.31. High yielding dividend stocks were amongst the top benefactors Friday as falling yields on government bonds sent investors flocking to stocks with high paying dividends. The S&P 500 is currently trading at price to forward earnings ratio of close to 17.8 as compared 25 year historic average of nearly 15, according to Reuters.

Register today for a
free membership and gain access to daily research reports at: RDInvesting.com

On Friday, the yield on the 10-year Treasury note dropped to 2.31 percent. In comparison, the S&P 500 Utilities sector spiked 4.3 percent for the week ended February 24th, its largest weekly gain since the week ended July 1st, 2016. The Utilities sector currently has a dividend yield of approximately 3.5 percent, according to FactSet.

“There was concern that the market was getting tired and that we were losing momentum, but there are still significant inflows, because now even the pessimists want a piece of the action. It’s momentum driven, not fundamentally driven,” said Lawrence Glazer, Managing Partner at Mayflower Advisors.

Let’s Take a
Closer Look at Today’s Trending Tickers

AGNC Investment’s shares gained 0.41 percent to close at $19.54 a share on Friday. The stock traded between $19.42 and $19.63 on volume of 2.33 million shares traded. The company currently offers investors an annualized dividend of $2.16 a share for a dividend yield of roughly 11.05 percent. AGNC Investment reported a net income of $3.06 per common share and comprehensive net loss which also includes net unrealized losses of $1.19 per common share for the fourth quarter of 2016. As of December 31, 2016, the Company’s net book value per common share was $21.17, compared to its September 30, 2016 net book value per common share of $22.91. Shares of AGNC Investment have gained approximately 7.78 percent year-to-date.

Access Today’s AGNC Investment Research
Report Click Here

Annaly Capital Management’s shares gained 0.64 percent to close at $11.05 a share on Friday. The stock traded between $10.95 and $11.07 on volume 7.06 million shares traded. The company currently offers investors an annualized dividend of $1.20 a share for a dividend yield of roughly 10.86 percent. AGNC Investment reported a GAAP net income of $1.8 billion, $1.79 per average common share, for the fourth quarter of 2016. As of December 31, 2016, the Company’s book value per common share was $11.16, compared to $11.83 at September 30, 2016. Shares of Annaly Capital Management have gained approximately 10.83 percent year-to-date.

Access Today’s Annaly Capital Management
Research Report Click Here

Today’s Features Includes:

AGNC Investment Corp. (NASDAQ: AGNC)

Annaly Capital Management, Inc. (NYSE: NLY)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 456023